Small molecules, big impact: 20 years of targeted therapy in oncology
Authors:
Top Cited Papers
- 1 March 2020
- journal article
- review article
- Published by Elsevier in The Lancet
- Vol. 395 (10229) , 1078-1088
Abstract
No abstract availableKeywords
This publication has 114 references indexed in Scilit:
- Pazopanib versus Sunitinib in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2013
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell CarcinomaNew England Journal of Medicine, 2012
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III TrialJournal of Clinical Oncology, 2012
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- Selectivity and therapeutic inhibition of kinases: to be or not to be?Nature Immunology, 2009
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- The Hallmarks of CancerCell, 2000